Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.82 |
| ▸ | GAK | O14976 | 3/20 | 0.82 |
| ▸ | FBP1 | P09467 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 1/20 | 0.82 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.70 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.70 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.70 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.70 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.70 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.68 |
| ▸ | BUB1 | O43683 | 2/20 | 0.68 |
| ▸ | STK10 | O94804 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL643709 | 0.99 | EGFR (0.81) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL1999903 | 0.96 | EGFR (0.74) | EGFRGAKFBP1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL2004303 | 0.95 | EGFR (0.73) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL667895 | 0.91 | EGFR (1.00) | EGFRGAKFBP1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1507455 | 0.90 | EGFR (0.98) | EGFRGAKFBP1ALDH1A1MAPT | |
| Acetic Acid SCHEMBL28392670 | 0.86 | EGFR (0.76) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL5240218 | 0.85 | EGFR (0.79) | EGFRGAKRIPK2STK10LCK | |
| SCHEMBL17967504 | 0.85 | EGFR (0.70) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL31424975 | 0.85 | HDAC3 (0.82) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL641646 | 0.85 | HDAC3 (0.82) | EGFRGAKFBP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609875-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3-MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | NATCO PHARMA LTD (IN) | 2021-10-20 | — | — | EP | disclosed |
| US-11091470-B2 | Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride | NATCO PHARMA LIMITED (IN) | 2021-08-17 | — | — | US | disclosed |
| US-20200331899-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3- MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | NATCO PHARMA LIMITED (IN) | 2020-10-22 | — | — | US | disclosed |
| CN-108658946-B | Novel quinazoline inhibitors | 焦玉奇 | 2020-06-16 | — | — | CN | disclosed |
| CN-107674059-B | Benzaheteroaromatic ring compound and preparation method and application thereof | 中国药科大学 | 2020-04-14 | — | — | CN | disclosed |
| EP-2780342-B1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-06-01 | — | — | EP | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181277-B2 | Aminoquinazoline derivatives and their salts and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-10 | — | — | US | disclosed |
| EP-2780342-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-08-14 | — | — | US | disclosed |
| WO-2009035718-A1 | TARTRATE SALTS OR COMPLEXES OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090036676-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | HIMMELSBACH FRANK | 2009-02-05 | — | — | US | disclosed |
| WO-2008033748-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20060270672-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | HIMMELSBACH FRANK | 2006-11-30 | — | — | US | disclosed |
| US-7119084-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-10 | — | — | US | disclosed |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | disclosed |
| US-6924285-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2005-08-02 | — | — | US | disclosed |
| EP-1492536-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | disclosed |
| WO-2003082290-A1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228361-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | ABL1, PRKDC, JAK2 | EGFR 460/4885GAK 180/4885FBP1 4095/4885 |
| US-20060270672-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B2, CYP11B1, HPGD | EGFR 1233/4885GAK 1108/4885FBP1 1166/4885 |
| US-11091470-B2 | Process for the preparation of N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride | MAP7, NQO2, ABL1 | EGFR 2563/4885GAK 2941/4885FBP1 4221/4885 |
| US-20090036676-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B2, CYP11B1, HPGD | EGFR 1233/4885GAK 1108/4885FBP1 1166/4885 |
| US-20200331899-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3- MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE | PAH, NQO2, MAP7 | EGFR 2948/4885GAK 3284/4885FBP1 4319/4885 |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B2, CYP11B1, HPGD | EGFR 1233/4885GAK 1108/4885FBP1 1166/4885 |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B1, AR, CYP11B2 | EGFR 221/4885GAK 1085/4885FBP1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.